NYAS Conferences
New York Academy of Sciences
left end
Search
divider divider feedback right end
Annals of the New York Academy of Sciences Annals of the New York Academy of Sciences login

Main

Browse Volumes

Forthcoming Volumes

Annals PrePrints

Annals Extra

E-mail Alerts

Subscriptions & Orders

New Proposals

Author Guidelines

About Annals

Help

Get free Annals volume as a NYAS member: http://www.nyas.org/annalsreaderhw
Issue 1089 coverEstrogens and Human Diseases Volume 1089 published November 2006
Ann. N.Y. Acad. Sci. 1089: 373–382 (2006). doi: 10.1196/annals.1386.004
Copyright © 2006 by the New York Academy of Sciences
description | purchase volume purchase this volume

This Volume
Table of Contents
Description
This Article
Full Text
Full Text (PDF)
Services
Similar articles in this journal
Similar articles in PubMed
Alert me to new issues of the journal
Download to citation manager
Citing Articles
Citing Articles via Google Scholar
Google Scholar
Articles by RAGONESE, P.
Articles by SAVETTIERI, G.
Search for Related Content
PubMed
PubMed Citation
Articles by RAGONESE, P.
Articles by SAVETTIERI, G.

Part VI. Estrogens and Neurodegenerative Disorders

Implications for Estrogens in Parkinson's Disease

An Epidemiological Approach

PAOLO RAGONESEa, MARCO D'AMELIOa AND GIOVANNI SAVETTIERIa

a Dipartimento Universitario di Neuroscienze Cliniche, Università di Palermo, Palermo, Italy

Key Words: Parkinson's disease • epidemiology • risk factors • fertile life • age at menopause • women

Address for correspondence: Giovanni Savettieri, M.D., Dipartimento Universitario di Neuroscienze Cliniche, Università di Palermo, Via Gaetano La Loggia 1-90129 Palermo, Italy. Voice: +39-091-6555146; fax: +39-091-6555147.  e-mail: gsavetti{at}tin.it

Evidence from experimental and epidemiological studies suggests a role of sex hormones in the pathogenic process leading to neurodegenerative diseases, (i.e., Alzheimer's and Parkinson's disease). The effects of sexual steroid hormones are complex and vary with the events of women's fertile life. Estrogens are supposed to influence dopamine synthesis, metabolism, and transport; however, there is no consensus regarding the direction, locus, and mechanism of the effect of estrogens on the dopaminergic system. A neuroprotective effect of estrogens has been demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-animal models of Parkinson's disease (PD). Epidemiological studies indicate gender differences regarding the onset and the prognosis of PD. Most of the analytical studies explored the relationship between PD and exogenous estrogens. Only three studies investigated the role of endogenous estrogens in the risk of developing PD. These studies reported an increased risk of PD in conditions causing an early reduction in endogenous estrogens (early menopause, reduced fertile life length). Longer cumulative length of pregnancies has also been associated with an increased PD risk. A lack of consensus still exists on the effect of the type of menopause (surgical vs. natural) on PD risk. Finally, the effect of postmenopausal estrogen replacement therapy is still debated. Inconsistencies across studies are in part explained by the complexity of the mechanisms of action of sexual hormones and by the paucity of analytical studies.






footerLeft footerRight